WO2002039982A1 - Composition pharmaceutique a administration orale liberee au niveau colique et son procede de preparation - Google Patents

Composition pharmaceutique a administration orale liberee au niveau colique et son procede de preparation Download PDF

Info

Publication number
WO2002039982A1
WO2002039982A1 PCT/CN2001/000919 CN0100919W WO0239982A1 WO 2002039982 A1 WO2002039982 A1 WO 2002039982A1 CN 0100919 W CN0100919 W CN 0100919W WO 0239982 A1 WO0239982 A1 WO 0239982A1
Authority
WO
WIPO (PCT)
Prior art keywords
pectin
capsule
metal salt
calcium
drug
Prior art date
Application number
PCT/CN2001/000919
Other languages
English (en)
French (fr)
Inventor
Junshou Zhang
Original Assignee
Zhang, Hao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhang, Hao filed Critical Zhang, Hao
Priority to AU2001272314A priority Critical patent/AU2001272314A1/en
Priority to BR0111757-2A priority patent/BR0111757A/pt
Priority to EP01951330A priority patent/EP1297828B1/en
Priority to DE60136813T priority patent/DE60136813D1/de
Priority to US10/297,529 priority patent/US20040022845A1/en
Priority to JP2002542357A priority patent/JP2004513182A/ja
Priority to CA002411045A priority patent/CA2411045A1/en
Publication of WO2002039982A1 publication Critical patent/WO2002039982A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the invention relates to a colon-specific localized oral preparation and a preparation method thereof.
  • 5,840,332 discloses a gastrointestinal drug delivery system including the colon, in which the water-insoluble material pectin calcium is used, wherein the content of calcium in the pectin is 2 to 4% by weight .
  • This document only gives an embodiment of preparing sodium salicylate tablets using pectin calcium and the release results of the prepared tablets in the stomach, and does not give a specific embodiment of a pectin-containing capsule preparation.
  • the object of the present invention is to find and develop oral formulations for colon-specific release.
  • the oral preparation in the present invention refers to a tablet or capsule.
  • a first aspect of the present invention relates to a capsule-released capsule preparation that includes a drug, a pectin metal salt having a metal content of 5-12% by weight, and other medicinal additives or excipients.
  • a further aspect of the invention relates to a colon-targeted release tablet comprising a tablet core containing a drug and pectin metal salt particles having a metal content of 5-12% (w / w).
  • a further aspect of the present invention relates to a method for preparing the capsule preparation of the present invention, which comprises: a) mixing a drug with a pharmaceutically acceptable excipient or additive and making into pellets;
  • pectin shells with a metal content of 5-12% (w / w) are prepared.
  • Another aspect of the present invention relates to a method for preparing a colon-targeted release tablet, which comprises compressing a tablet core containing a drug and pectin metal salt particles with a metal content of 5-12% (w / w) into a chip-wrapped chip by a dry pressing method. Or after compressing the drug with a pectin metal salt with a metal content of 5-10 wt% and an appropriate amount of other excipients into a tablet core, spray coating or tablets with a coating agent such as an ethanol solution of an acrylic polymer.
  • a coating agent such as an ethanol solution of an acrylic polymer.
  • the medicine in the capsule preparation of the present invention is selected from the group consisting of anti-inflammatory drugs, antibacterial agents, anticancer agents, immunosuppressive agents, cardiovascular drugs, anti-colitis agents, various Chinese medicines, and the like.
  • anti-inflammatory drug includes steroidal or non-steroidal anti-inflammatory drugs, such as indomethacin, hydrocortisone, and the like.
  • the term “immunosuppressive agent” includes, for example, cyclosporin and the like.
  • the term “cardiovascular drug” includes, for example, nifedipine.
  • anticancer drug includes, for example, 5-fluorouracil.
  • anicolitis agent includes, for example, 5-aminosalicylic acid and the like.
  • Chinese medicine includes Chinese medicine for treating or preventing various diseases or symptoms, such as Chinese medicine for regulating immune function and antibacterial and anti-inflammatory, and Chinese medicine for treating diabetes. And traditional Chinese medicine for treating hypertension.
  • the invention relates to a capsule-released capsule preparation, which comprises a drug, a pectin metal salt with a metal content of 5-12% (w / w), a medicinal carrier or excipient, and a common capsule shell.
  • the invention also relates to a capsule-released capsule preparation comprising a drug, a pharmaceutically acceptable carrier or an excipient, and a capsule shell containing a pectin metal salt having a metal content of 5-12% (w / w).
  • the colon-targeted capsule preparations of the present invention include: pellets containing drugs and medicinal excipients or additives, pectin-containing metal coating with 5-12% (w / w), and acrylic polymerization Coating, and ordinary micellar shell.
  • preferred colonic release capsules include 5-aminosalicylic acid-containing pellets, a pectin calcium coating with a calcium content of 5-12% (w / w), an acrylic polymer coating, and a common gum. ⁇ shell.
  • a colon-targeted release capsule preparation preferably contains 5-aminosalicylic acid, a pharmaceutically acceptable carrier or excipient, and pectin calcium with a calcium content of 5-12% (w / w) and a water content of 6-10% (w / w) Capsule shell.
  • the present invention also relates to a colon-targeted oral tablet comprising a tablet core containing a drug and pectin metal salt particles having a metal content of 5-12% (w / w).
  • the present colon-targeted oral tablet includes a core containing 5-aminosalicylic acid and pectin calcium granules having a molybdenum content of 5-12% (w / w).
  • the oral tablet of the present invention includes a drug (such as 5-aminosalicylic acid) containing a metal content such as a pectin metal salt (calcium pectin) of 5-12% (w / w), a tablet core, and Coating agent.
  • a drug such as 5-aminosalicylic acid
  • a metal content such as a pectin metal salt (calcium pectin) of 5-12% (w / w)
  • a tablet core such as a tablet core, and Coating agent.
  • the present invention also relates to a method for preparing a colon-specific release capsule preparation comprising:
  • the invention also relates to a method for preparing colon-targeted oral tablets, which comprises a tablet core containing a drug and pectin metal salt particles with a metal content of 5-12% (w / w), which are compressed into a chip-encapsulating agent by a dry pressing method;
  • the drug is compressed into a tablet core with a pectin metal salt having a metal content of 5-12% by weight and an appropriate amount of other excipients, and then spray-coated with a coating agent such as an ethanolic solution of an acrylic polymer into a tablet.
  • the invention also relates to a colon-targeted release capsule preparation prepared by the method described above.
  • the drug in the capsule preparation of the present invention is preferably 5-aminosalicylic acid.
  • the pectin metal salt used in the present invention is selected from the group consisting of calcium pectin, iron pectin or zinc pectin, preferably calcium pectin.
  • the pharmaceutically acceptable carrier or excipient in step a) may be selected from at least one of the following, for example, starch, microcrystalline cellulose, sucrose, lactose, mannitol, water, ethanol-water, polyvinylpyrrolidone Ethanol solution, hydroxypropyl methylcellulose slurry, low-substituted hydroxypropyl cellulose, sodium carboxymethyl starch, etc.
  • the pellets can be prepared by centrifugal granulation method or extrusion method or high-speed stirring granulation method.
  • step b) the coating of the pellets by the pectin metal salt is performed as follows.
  • the pellets are sprayed with a metal salt such as CaCl 2 ethanol solution (concentration 1-8% (w / w)) while rolling,
  • a metal salt such as CaCl 2 ethanol solution (concentration 1-8% (w / w)) while rolling.
  • the pellets with CaCl 2 are then immersed in an aqueous pectin solution for 15-60 minutes, and then immersed in a warm metal salt such as CaCl 2 ethanol.
  • the acrylic polymer used is selected from EudragitL or Eudragit S.
  • the capsule shell containing a pectin metal salt with a metal content of 5-12% (w / w) and a water content of 6-10% by weight in step a ') is prepared as follows:
  • Oxygen pectin is selected from the group consisting of formaldehyde, glutaraldehyde, sodium alginate, gelatin, gum arabic, pick gum, methyl cellulose, ethyl cellulose, polyvinylpyrrolidone, hydroxypropyl methyl cellulose, chitosan or Acrylic resin cross-linking agent, selected from propylene glycol, glycerin, diethyl behenate, dibutyl sebacate, tributyl citrate or castor oil plasticizer and water mixing, 50 ° C heat preservation degassing , Forming a glue solution;
  • a metal salt such as CaCl 2 ethanol solution for calcification
  • the method for preparing an oral tablet according to the present invention wherein the tablet core is prepared as follows: A drug such as 5-aminosalicylic acid is mixed with one or more drug carriers selected from microcrystalline cellulose, starch, lactose and the like, and starch is added thereto. The pulp or polyvinylpyrrolidone ethanol solution or 50% ethanol is used to make a soft material, sieved and granulated, dried, granulated, and mixed with 1% disintegrating agent such as magnesium stearate to obtain the desired core.
  • a drug such as 5-aminosalicylic acid
  • one or more drug carriers selected from microcrystalline cellulose, starch, lactose and the like
  • starch is added thereto.
  • the pulp or polyvinylpyrrolidone ethanol solution or 50% ethanol is used to make a soft material, sieved and granulated, dried, granulated, and mixed with 1% disintegrating agent such as magnesium stearate to obtain the desired core.
  • the preparation of calcium pectin granules is as follows: Firstly, commercially available pectin is treated by ion exchange method or acidified alcohol method to purify pectin, and then pectin is purified by treating with acid and alkali to obtain deesterified pectin, that is, low-methyl Low-methoxy pectin is formulated into an aqueous solution and added dropwise to a certain concentration of calcium ion ethanol solution to obtain a pectin calcium precipitate. The obtained precipitate is washed, dried and pulverized, and then selected from starch slurry and gelatin. Pulp, pick glue solution, HPMC pulp, MC pulp or EC pulp granules to obtain the desired pectin calcium Particles.
  • Colon-localized release capsules of 5-aminosalicylic acid are prepared by treating the above ingredients in steps -a) -c) of the aforementioned method of the present invention.
  • Example 2 Preparation of pectin-containing calcium coriander shell
  • LMP low methoxyl pectin
  • Example 8 Colon-localized release tablet ingredients of 5-aminosalicylic acid
  • 5-ASA and CMS-Na are mixed with 4% HPMC liquid to make soft materials, granulated through a 20-mesh sieve, dried and granulated, mixed with talc, mixed with talcum powder and punched with ⁇ 7 ⁇ , a shallow concave punch, for core use.
  • Ingredient amount 4% HPMC liquid to make soft materials, granulated through a 20-mesh sieve, dried and granulated, mixed with talc, mixed with talcum powder and punched with ⁇ 7 ⁇ , a shallow concave punch, for core use.
  • Chinese Pharmacopoeia 95 tablets dissolution method was used for determination.
  • the medium for 0-2 hours is an aqueous solution of pH 1.2, the phosphate buffer solution at pH 6.8 is replaced for 3-7 hours, and the pectinase solution or rat cecum content solution is used for 8-24 hours.
  • the speed is 50r / min and the temperature is 37 ° C. 0.5
  • the results are shown in Figure 1 and Figure 2.
  • the release rate of the tablet of Example 8 is 1% within 2 hours in the medium with pH 1.2, and 10% within 5 hours in the pH 6.8 medium, that is, within 0-7 hours.
  • the amount did not exceed 15%, and in 8-23 hours, whether it was pectinase or the contents of the rat cecum, the drug release was> 85%, indicating that the colon-targeted drug release requirement was reached.
  • Example 13
  • Example 8 Tablets prepared similar to that described to prepare the 99m Tc0 4 -cap sheet in place of 5-aminosalicylic acid 99m Tc0 4 with concentrated aqueous solution, so that two healthy volunteers fasting oral tablets 99m Tc0 4 -cap At 2, 5, and 23 hours, ⁇ -scintillation photography was used to carry out human body static imaging. The results show that 99m Tc0 4 -pectin calcium tablets in human stomach and small The intestine can basically maintain the original shape of the tablet, prevent the leakage of 99m Tc0 4 , can pass through the stomach and small intestine safely, and is completely released in the colon.
  • the 1-hour human scintillation photograms are not marked with positioning marks, and the small bright spots above 5 hours and 23 hours are the positioning marks.
  • the tablet was intact in the stomach 2 hours after taking it, without any change; it had entered the small intestine within 5 hours, and the tablet was slightly swollen, but basically maintained the tablet shape; the tablet completely disintegrated in 23 hours, and the radioisotope 99m Tc0 4 had Diffuse throughout the ascending, transverse, and descending colons.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

结肠定位释放的口服制剂及其制备方法 发明领域
本发明涉及结肠定位释放的口服制剂及其制备方法
先有技术
许多药物由于各种原因不能通过胃肠道很好的释放。 举例 讲, 人体结肠部位的病变或症状通常为结肠炎, 溃疡性结肠炎或 结肠癌等, 由于上述疾病或症状部位背处于胃肠道深部, 口服给 药时药物通常在小肠上端吸收, 结肠处药物浓度很低甚至没有, 灌肠或栓剂给药只能作用到直肠或乙状结肠, 不能到达升结肠和 横结肠且用药不方便。 E. Itzbak lerner等人在美国专利 5, 840, 332 中披露了包括结肠的肠胃道给药系统, 其中使用了水不溶性材料 果胶钙, 其中钙在果胶中的含量为 2 - 4重量%。 该文献仅给出使 用果胶钙制备水杨酸钠片剂实施方案及所制备的片剂在胃中的释 放结果, 并没有给出含果胶 的胶嚢制剂的具体实施方案。
因此, 寻找并开发于结肠定位释放的胶嚢制剂给药系统是非 常重要的。
发明目的
本发明的目的在于寻找并开发于结肠定位释放的口服制剂。 发明简述
本发明人经广泛深入的研究, 现已出人意料地发现含有金属 含量 5 - 12重量%的果胶金属盐的胶嚢制剂在结肠中有很好的定 位释放效果, 本发明基于上述发现得以完成。
根据本发明, 本发明中的口服制剂是指片剂或胶嚢。
本发明第一方面涉及结肠定位释放的胶嚢制剂, 其包括药 物, 金属含量为 5 - 12重量%的果胶金属盐及其它药用添加剂或 赋形剂。 本发明再一方面涉及结肠定位释放的片剂, 其包括含有药物 的片芯和金属含量 5- 12% (w/w) 的果胶金属盐颗粒。
本发明再一方面涉及制备本发明胶嚢制剂的方法, 其包括: a)将药物与药用赋形剂或添加剂混合, 并制成微丸;
b)将 a)中形成的微丸用就地生成的钙含量 5-12% (w/w) 的果胶金属盐包衣;
c)将 b)中包衣用丙烯酸聚合物的乙醇熔液喷雾包衣, 然后装 入明胶胶嚢, 或
a')首先制备金属含量 5-12% (w/w) 的果胶金属盐的胶嚢 壳,
b')将药物装入 a')制备的胶嚢壳中。
本发明再一方面涉及制备结肠定位释放的片剂的方法, 其包 括将含有药物的片芯与金属含量 5- 12% (w/w)的果胶金属盐颗 粒通过干压法压制成包芯片剂; 或将药物与金属含量 5- 10wt% 的果胶金属盐及适量其它赋形剂压成片芯后, 再以包衣剂如丙烯 酸聚合物的乙醇溶液喷雾包衣或片剂。
根据本发明,本发明胶嚢制剂中的药物选自抗炎药,抗菌剂, 抗癌剂, 免疫抑制剂, 心血管药、 抗结肠炎剂, 各种中药等。
根据本发明, 术语 "抗炎药" 包括甾类或非甾类抗炎药, 例 如消炎痛, 氢化可的松等。
根据本发明, 术语 "免疫抑制剂" 包括例如环孢菌素等。 根据本发明, 术语 "心血管药" 包括例如硝苯地平等。
根据本发明, 术语 "抗癌药" 包括例如 5-氟尿嘧啶。
根据本发明, 术语 "抗结肠炎剂" 包括例如 5-氨基水杨酸 等。
根据本发明, 术语 "中药" 包括治疗或预防各种疾病或症状 的中药, 例如调节免疫功能和抗菌消炎的中药, 治疗糖尿病的中 药和治疗高血压的中药等。
本发明详细描述
本发明涉及结肠定位释放的胶嚢制剂, 其包括药物, 金属含 量为 5- 12% (w/w)的果胶金属盐, 药用载体或赋形剂及普通胶 嚢壳。
本发明还涉及结肠定位释放的胶嚢制剂, 其包括药物, 药用 载体或赋形剂及含有金属含量为 5 - 12% (w/w)的果胶金属盐的 胶嚢壳。
更具体讲, 本发明的结肠定位释放的胶嚢制剂包括: 含药物 和药用赋形剂或添加剂的微丸, 含 5- 12% (w/w)的果胶金属盈 包衣及丙烯酸聚合物包衣, 和普通胶束壳。
根据本发明, 优选结肠定位释放的胶嚢剂包括含 5-氨基水 杨酸的微丸, 钙含量 5-12% (w/w)的果胶钙包衣, 丙烯酸聚合 物包衣及普通胶嚢壳。
根据本发明,优选结肠定位释放胶嚢制剂含 5-氨基水杨酸, 药用载体或赋形剂, 及钙含量 5- 12% (w/w)的果胶钙且水含量 6-10% (w/w)胶嚢壳。
根据本发明, 本发明还涉及结肠定位的口服片剂, 其包括含 有药物的片芯及金属含量 5- 12% (w/w) 的果胶金属盐颗粒。
更具体讲, 本结肠定位释放的口服片剂, 其包括含 5-氨基 水杨酸的片芯及钼含量 5- 12% (w/w) 的果胶钙颗粒。
根据本发明, 本发明的口服片剂包括含金属含量如钙含量 5 - 12% (w/w)的果胶金属盐(果胶钙)的药物(如 5-氨基水杨 酸) 片芯及包衣剂。
根据本发明, 本发明还涉及制备结肠定位释放的胶嚢制剂的 方法, 其包括:
a)将药物与药用载体或赋形剂混合并制成微丸; b)将 a)中的微丸用就地生成的果胶金属盐包衣, 包衣后的果 胶金属盐中的金属含量为 5- 12% (w/w) ;
c)将 b)中的包衣用丙烯酸聚合物的乙醇溶液喷雾包衣, 然后 装入普通明胶胶嚢, 或
a')制备含有金属含量 5-12% (w/w) 的果胶金属盐且水含 量为 6- 10重量%的胶嚢壳,
b')将药物装入 a')中制备的胶嚢壳中。
本发明还涉及制备结肠定位释放的口服片剂的方法, 其包括 含药物的片芯与金属含量 5- 12% (w/w)的果胶金属盐颗粒通过 干压法压制成包芯片剂; 或将药物与金属含量 5- 12wt%的果胶 金属盐及适量其它赋形剂压成片芯后, 再以包衣剂如丙烯酸聚合 物的乙醇溶液喷雾包衣成片剂。
本发明还涉及由上述方法制备的结肠定位释放的胶嚢制剂。 根据本发明, 本发明胶嚢制剂中的药物优选是 5-氨基水杨 酸。
根据本发明, 本发明中所用的果胶金属盐选自果胶钙, 果胶 铁或果胶锌, 优选果胶钙。
根据本发明的方法, 其中步骤 a)中的药用载体或赋形剂可选 自下面至少一种例如淀粉, 微晶纤维素, 蔗糖, 乳糖、 甘露醇, 水, 乙醇-水, 聚乙烯吡咯烷酮乙醇液, 羟丙甲基纤维素浆液, 低取代羟丙基纤维素, 羧甲基淀粉钠等, 其中的微丸可通过离心 造粒法或挤压法或高速搅拌制粒法制得。 在步驟 b)中, 果胶金属 盐对微丸的包衣是如下进行的, 微丸在滚动下, 往上喷金属盐如 CaCl2乙醇液(浓度 1- 8% (w/w) ) , 然后将带有 CaCl2的微丸 浸入果胶水溶液 15-60分钟, 然后再浸入温热的金属盐如 CaCl2 乙醇液中。 在步驟 C中, 所用的丙烯酸聚合物选自 EudragitL或 Eudragit S。 根据本发明方法, 步骤 a')中含有金属含量 5 - 12 % ( w/w ) 的果胶金属盐且含水量为 6 - 10重量%的胶嚢壳是如下制备的: i)将低甲氧基果胶与选自甲醛、 戊二醛, 海藻酸钠, 明胶, 阿拉伯胶, 挑胶, 甲基纤维素, 乙基纤维素, 聚乙烯吡咯烷酮, 羟丙甲基纤维素, 壳聚糖或丙烯酸树酯的交联剂, 选自丙二醇、 甘油、 笨二甲酸二乙酯, 癸二酸二丁酯, 柠檬酸三丁酯或蓖麻油 的增塑剂及水混合, 50°C保温脱气, 形成胶液;
ii) 往洁净模棒上涂作为润滑剂的液体石蜡,然后浸入 i)胶液 15秒至 1分钟后从胶液提出
iii)将 ii)中模棒浸入 0.1 - 10 % ( w/w )金属盐如 CaCl2乙醇 溶液中钙化, 于 40 - 80 保温 10分钟至 5小时;
iv)将 iii)中固化模棒于温度 30 - 60 , 相对湿度 30 - 40 %条 件下吹风干燥, 控制含水量在 6 - 10重量%;
V)如需要, 将 iv)所得模棒浸入 1一 10 % (重量 /体积)聚乙烯 吡咯烷酮溶液片刻后取出热风吹干, 再浸入 1 - 10 % (重量 /体积) 丙烯酸树脂片刻后, 取出热风吹干, 脱模、 按所需大小分割为所 要胶嚢壳。
根据本发明制备口服片剂的方法, 其中片芯如下制备: 将药 物如 5 -氨基水杨酸与一种或多种选自微晶纤维素, 淀粉, 乳糖 等药物载体混合, 往其中加入淀粉浆或聚乙烯吡咯烷酮乙醇液或 50 %乙醇制成软材, 过筛制粒, 干燥, 整粒, 加 1 %崩解剂如硬 脂酸镁混匀压片得所要片芯。 果胶钙颗粒的制备如下: 首先通过 离子交换法或酸化醇法处理市售果胶, 从而纯化果胶, 然后通过 用酸和碱处理纯化果胶, 得脱酯化的果胶, 即低甲氧基果胶, 将 低甲氧果胶配成水溶液, 并滴加到一定浓度钙离子乙醇溶液中, 得果胶钙沉淀, 将所得沉淀洗涤, 干燥和粉碎后, 用选自淀粉浆、 明胶浆、 挑胶液、 HPMC浆、 MC浆或 EC浆剂粒得所要果胶钙 颗粒。
下面的实施例用以进一步说明本发明, 但应明白本发明并不 仅限于此。
实施例 1
5 -氨基水杨酸的结肠定位释放胶嚢
成分 量
5-氨基水杨酸 125g
淀粉 25g
糊精 3.6g
3%氯化钙乙醇液
将上述成分按本发明前述方法的步- a) -c)处理制得 5-氨 水杨酸的结肠定位释放胶嚢。 实施例 2 含果胶钙嚢壳的制备
成分 量
15 %低甲氧基果胶( LMP ) 水溶液 100ml
5 % CaCl2乙醇-水( 7:3 ) 溶液 100ml
5%PVP乙醇液 100ml
8%丙烯酸 II号树脂醇液 100ml
往洁净模棒上涂液状石蜡,然后浸入 15% LMP液 30秒后提 出, 再浸入 5% CaCl2乙醇( 70% ) 液, 钙化( 60°C ) 1小时, 置 于 35%、 RH35%条件下吹干, 再浸入 5% PVP乙醇液 2分钟, 提 出置 35 、 RH35%条件下吹至近干, 后浸入 8%再烯酸 II号树 脂醇液 1分钟, 提出吹干即成果胶钙胶嚢壳。 实施例 3 含果胶下的胶囊壳制备
成分 15 %低甲氧基果胶( LMP ) 水溶液 100ml
阿拉伯胶或挑胶 2g
丙二醇 2ml
5% CaCl2乙醇-水( 7:3 )溶液 100ml
5%PVP乙醇液 100ml
8%丙烯酸 II号树脂醇液 100ml
将阿拉伯胶或挑胶溶于 LMP液或分别将 LMP与阿拉伯胶 或挑胶溶于适量水中后混匀, 加丙二醇混匀作胶液, 其余搡作与 实施例 2相同。 实施例 4 含果胶钙的胶嚢壳制备
成分 量
15 %低甲氧基果胶( LMP ) 水溶液 100ml 明胶或甲基纤维素或羟丙甲纤维素或海藻酸钠 2g 甘油 2g
5 % CaCl2乙醇-水( 7:3 )溶液 100ml 5%PVP乙醇液 100ml 8%丙烯酸 II号树脂醇液 100ml 制法同实施例 3 实施例 5 含果胶钙的胶嚢壳制备
成分 量
15%低甲氧基果胶 ( LMP ) 水溶液 100ml
5%乙基纤维素乙醇液 100ml
苯二甲酸二乙酯或癸二酸二丁酯 i .25g
5 % CaCl2乙醇-水( 7:3 )溶液 100ml
5%PVP乙醇液 100ml 往洁净模棒上涂液状石蜡, 然后浸入 15% LMP液 1分钟后 取出, 再浸入 5%CaCl2乙醇(70% )液, 60°C钙化 1小时, 置于 30"C、 RH75%条件下吹干, 浸入 5%PVP乙醇液 2分钟, 提出置 35°CRH35%条件下吹至近干,再浸入加有苯二甲酸二乙酯或癸二 酸二丁酯的乙基纤维素乙醇液 30 秒, 提出吹干即成果胶钙胶嚢 壳。 实施例 6
果胶钙的制备:
成分:
果胶 15g
氨水 250ml
乙醇 400ml
CaCl2 80g
蒸馏水 适量
果胶均匀混悬于乙醇氨水混合液中搅拌 6小时, 抽滤, 滤渣 以乙醇洗涤, 60 干燥, 过 100 目筛, 置 60 °C水浴溶于 2000ml 蒸馏水中, 将 5%CaCl2溶液 1000ml加入搅勾 1小时, 抽滤后, 滤渣用蒸馏水洗至无 C1止, 80 干燥, 粉碎成 100目细粉, 用原 子吸收光谱法测得钙含量 9.43wt%。 实施例 7 5 -氨基水杨酸的结肠定位释放胶嚢
成分 量
5-氨基水杨酸 125g
L HPC 5g
滑石粉 3.9g/1000粒
制备: 上述各组份混句后装入实施例 2- 5制备的胶嚢即可。 实施例 8 5-氨基水杨酸的结肠定位释放片剂 成分 量
5-氨基水杨酸 125g
果胶钙 200g
5%乙基纤维素乙醇液 适量
HPMC 50g
滑石粉 3%/1000片
制备: 将 5-氨基水杨酸、 果胶钙、 HPMC混匀加 5%乙基 纤维素乙醇液制软材, 过筛制粒, 50°C干燥、 整粒加滑石粉混匀 压片, 以 8%丙烯酸树脂 III号醇液包衣。 结肠定位释放片剂的制备
成分 里 成分 里
5 -氨基水杨酸 125g 果酸钙 375g 乳糖 25g HPMC 100g
10 %淀粉浆 适量 10%乙基纤维素醇液 100g 滑石粉 30% 硬脂酸镁 适量
将 5 -氨基水杨酸与乳糖混句加 10%淀粉浆制软材, 过筛、 制粒、 50%干燥、 整粒, 加滑石粉混匀压片(7mm冲)即为片芯; 另将果胶钙与 HPMC混匀后, 加 10%乙基纤维素醇液制软材, 过筛制粒, 60* 干燥后, 整粒, 加滑石粉混匀后, 在 φΐΐιηιη冲模 中将上述片芯压制成干压包衣片。 5-氨基水杨酸(5- ASA) 的结肠定位释放片 ( 1000片) 成分
5-氨基水杨酸 125g 羧丙甲纤维素(HPMC) 25g
卡波姆(Carbopol) 10g
乙基纤维素(EC) 10g
果胶钙( Cap ) 200g
95%乙醇 适量 包衣液为 6%丙烯酸树脂肠包衣液
按所述量称取 5- ASA、 HPMC. CarbopoL EC、 Cap细粉 混匀后, 以 80%乙醇制软材, 过 22目筛制后, 50Ό烘干, 整粒, 加适量滑石粉混匀后以 (j)9mm浅凹冲压片, 用上述包衣液包衣。 实施例 11
5 -氨基水杨酸的结肠定位释放干压包芯片 ( 1000片)
成分 量
5 -氨基水杨酸 125g
羧甲基淀粉钠 10g
4% HPMC液 适量
滑石粉 4.0g
5 - ASA与 CMS - Na混匀以 4% HPMC液制软材,过 20目 筛制粒, 50 烘干, 整粒, 加滑石粉混匀后以 φ7ιηιη浅凹冲压片, 作片芯用。 成分 量
果胶钙 200g
HPMC 30g
阿拉伯胶 20g
10%乙基纤维素醇液 适量
滑石粉 7.5g
果胶钙、 HPMC、 阿拉伯胶混匀, 以 10%乙基纤维素醇液制 软材, 过 18目筛制粒, 50" 烘干, 整粒, 加滑石粉混匀, (每个 片芯用约 0.3g- Cap颗粒) 以 φΐΐιηιη浅凹冲压片。 实施例 12
实施例 8的片剂中 5 -氨基水杨酸的体外释放度
采用中国药典 95片溶出度二法测定。 0 - 2小时介质为 pHl.2 水溶液, 3- 7小时更换 pH6.8的磷酸緩冲液, 8- 24小时采用果 胶酶溶液或大鼠盲肠内容物溶液。 转速为 50r/分钟, 温度为 37土 0.5 结果见图 1与图 2。
由图 1、 2可知实施例 8片剂在 pH1.2的介质中 2小时内释 药为 1% \在 pH6.8介质中 5小时内释药 10% \即在 0-7小时 内释药量未超过 15%, 而在 8- 23小时间, 无论以果胶酶还是以 大鼠盲肠内容物,释药量均>85% ,表明已达结肠定位释药之要求。 实施例 13
99mTc04片在人体内靶向验证
类似于实施例 8片剂的制备方法, 用浓缩后的 99mTc04水溶 液代替 5-氨基水杨酸制成了 99mTc04-cap片,让两名健康志愿者 空腹口服 99mTc04-cap片, 分别于 2、 5、 23小时用 γ -闪烁照相 进行人体静位显像。 结果表明, 99mTc04-果胶钙片在人体胃和小 肠中能基本保持片剂原形, 防止 99mTc04的泄漏, 能安全通过胃 和小肠, 而在结肠中完全释放, 从 23小时时 99mTc04 -果胶钙片 的体内闪烁照相图中看出 99mTc04已几乎弥散地分布于整个结肠, 故可认为所制备的果胶钙具有结肠靶向释药性能,制备的 99mTc04 -果胶钙片符合人体靶向给药的要求, 99mTc04果胶钙片剂在 2、 5、 23小时的 γ -闪烁照相图见图 3、 4、 5。
注: 1小时人体 γ -闪烁照相图未作定位标记、 5小时、 23小 时上方小亮点即为定位标记物。 服后 2小时在胃内片形完整, 无 任何变化; 5 小时已进入小肠, 片形略有胀大, 但基本保持了片 形; 23小时片剂完全崩散, 而且放射性同位素 99mTc04已弥散分 布在整个升结肠、 横结肠、 降结肠。

Claims

权 利 要 求
1. 结肠定位释放的胶嚢制剂, 其包括药物, 金属含量为 5- 12 % (w/w) 的果胶金属盐, 及药用载体或赋形剂。
2. 权利要求 1 的胶橐制剂, 其中果胶金属盐选自果胶钙, 果 胶铁或果胶锌。
3. 权利要求 1或 2的胶嚢制剂, 其中果胶金属盐选自果胶钙。
4. 权利要求 1或 2的制剂,其包括选自 5-氨基水杨酸的药物, 药用载体或赋形剂, 及钙含量 5- 12% (w/w)果胶钙且水含量 6 - 10% (w/w) 的胶嚢壳。
5. 结肠定位释放的口服片剂, 其包括含有药物的片芯, 金属 含量 5 - 10%的果胶金属颗粒。
6. 权利要求 5的片剂, 其中药物选自 5-氨基水杨酸, 果胶金 属盐选自果胶钙。
7. 结肠定位释放的口服片剂, 其包括由药物、 金属含量 5- 12 % (w/w) 果胶金属盐、 药用载体或赋形剂组成的片芯, 和包衣 剂。
8. 权利要求 1-4任一要求的胶嚢制剂的制备方法, 其包括: a)将药物与药用赋形剂或添加剂混合, 并制成微丸;
b)将 a)中形成的微丸用就地生成的金属含量 5 - 12% (w/w) 的果胶金属盐包衣;
c)将 b)中包衣用丙烯酸聚合物的乙醇熔液喷雾包衣, 然后装 入明胶酸嚢, 或
a')首先制备含有金属含量为 5-12% (w/w) 的果胶金属盐 且水含量为 6- 10重量%的胶嚢壳,
b')将药物装入 a')制备的胶嚢壳中。
9. 适用于结肠定位释放胶嚢制剂的胶嚢壳, 其特征在于: 该 胶嚢壳含有金属含量为 5-12% (w/w)的果胶金属盐且含水量为 6- 10%。
10. 权利要求 9的胶嚢壳的制备方法, 其包括
i)将低甲氧基果胶与选自甲醛、 戊二醛, 海藻酸钠, 明胶, 阿拉伯胶, 挑胶, 甲基纤维素, 乙基纤维素, 聚乙烯吡咯烷酮, 羟丙甲基纤维素, 壳聚糖或丙烯酸树酯的交联剂, 选自丙二醇、. 甘油、 苯二甲酸二乙酯, 癸二酸二丁酯, 柠檬酸三丁酯或蓖麻油 的增塑剂及水混合, 50Γ保温脱气, 形成胶液;
ii) 往洁净模棒上涂作为润滑剂的液体石蜡,然后浸入 i)胶液 15秒至 1分钟后从胶液提出
iii)将 ii)中模棒浸入 0.1-10% (w/w)金属盐乙醇溶液中钙 化, 于 40- 保温 10分钟- 5小时;
iv)将 iii)中固化模棒于温度 30― 60 C , 相对湿度 30一 40%条 件下吹风干燥, 控制含水量在 6- 10重量%;
V)如需要, 将 iv)所得模棒浸入 1 - 10% (重量 /体积)聚乙烯 吡咯烷酮乙醇溶液片刻后取出热风吹干, 再浸入 1-10% (重量 / 体积) 丙烯酸树脂片刻后, 取出热风吹干, 脱模、 按所需大小分 割为所要胶嚢壳。
PCT/CN2001/000919 2000-06-07 2001-06-07 Composition pharmaceutique a administration orale liberee au niveau colique et son procede de preparation WO2002039982A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2001272314A AU2001272314A1 (en) 2000-06-07 2001-06-07 Oral formulations for localized colonic release and the method of preparation thereof
BR0111757-2A BR0111757A (pt) 2000-06-07 2001-06-07 Formulações oral para liberação colÈnica localizada e o método de preparação das mesmas
EP01951330A EP1297828B1 (en) 2000-06-07 2001-06-07 Oral formulations for localized colonic release and the method of preparation thereof
DE60136813T DE60136813D1 (de) 2000-06-07 2001-06-07 Orale formulierungen zur lokalen freisetzung im kolon und methode deren zubereitung
US10/297,529 US20040022845A1 (en) 2000-06-07 2001-06-07 Oral formulations for localized colonic release and the method of preparation thereof
JP2002542357A JP2004513182A (ja) 2000-06-07 2001-06-07 特異的結腸送達用経口製剤およびその製造法
CA002411045A CA2411045A1 (en) 2000-06-07 2001-06-07 Oral formulations for localized colonic release and the method of preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB001179896A CN1285333C (zh) 2000-06-07 2000-06-07 结肠定位释放的口服制剂及其制备方法
CN00117989.6 2000-06-07

Publications (1)

Publication Number Publication Date
WO2002039982A1 true WO2002039982A1 (fr) 2002-05-23

Family

ID=4587096

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/000919 WO2002039982A1 (fr) 2000-06-07 2001-06-07 Composition pharmaceutique a administration orale liberee au niveau colique et son procede de preparation

Country Status (10)

Country Link
US (1) US20040022845A1 (zh)
EP (1) EP1297828B1 (zh)
JP (1) JP2004513182A (zh)
KR (1) KR20030023869A (zh)
CN (1) CN1285333C (zh)
AU (1) AU2001272314A1 (zh)
BR (1) BR0111757A (zh)
CA (1) CA2411045A1 (zh)
DE (1) DE60136813D1 (zh)
WO (1) WO2002039982A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10844322B2 (en) 2012-08-07 2020-11-24 Ecolab Usa Inc. High flashpoint alcohol-based cleaning, sanitizing and disinfecting composition and method of use on food contact surfaces

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20021592D0 (no) * 2002-04-04 2002-04-04 Fmc Biopolymer As Polysakkaridkapsler og fremgangsmåte ved fremstilling derav
CN1456148A (zh) * 2003-03-26 2003-11-19 北京东方凯恩医药科技有限公司 胃肠动力药在制备结肠定位药物组合物中的用途
EP1991196B1 (en) * 2006-03-03 2016-10-12 Fmc Corporation Method and apparatus for the preparation of capsules.
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
ZA200903858B (en) * 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
CN101791298B (zh) * 2009-06-04 2011-09-14 徐州弘康科技有限公司 一种以果胶/玉米朊为包衣的结肠给药片
JP5496616B2 (ja) * 2009-11-18 2014-05-21 フロイント産業株式会社 大腸ドラッグデリバリーシステム製剤
US9433583B2 (en) 2011-04-22 2016-09-06 Frank J. Farrell Colon vitamin
JP5102401B1 (ja) * 2012-03-30 2012-12-19 森下仁丹株式会社 大腸特異崩壊性カプセル
IN2015DN00427A (zh) 2012-07-23 2015-06-19 Samsung Fine Chemicals Co Ltd
KR102085330B1 (ko) 2012-12-05 2020-03-05 롯데정밀화학 주식회사 두께 균일성이 개선된 경질 캡슐
KR102161001B1 (ko) * 2013-12-31 2020-09-29 롯데정밀화학 주식회사 경질 캡슐용 수성 조성물 및 이를 사용하여 제조된 경질 캡슐
CN104055750B (zh) * 2014-07-03 2016-09-21 王荣辉 具有靶向功能的空心胶囊及制备方法
JP6780412B2 (ja) * 2016-09-28 2020-11-04 ライオン株式会社 コーティング組成物ならびにコーティング製剤及びその製造方法
CN109453132B (zh) * 2018-12-31 2021-04-16 正大青春宝药业有限公司 一种治疗冠心病的时滞控释片剂及其制备方法
CN114224860B (zh) * 2021-11-06 2023-04-28 山东润德生物科技有限公司 氨基葡萄糖钙片制剂及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1208343A (zh) * 1996-01-18 1999-02-17 派利欧产品有限公司 胃肠内释药体系
WO1999018938A1 (en) * 1997-10-09 1999-04-22 Perio Products Ltd. Delayed total release gastrointestinal drug delivery system
WO2000028974A1 (en) * 1998-11-12 2000-05-25 Dexxon Ltd. Local delivery of drugs to the colon for local treatment of colonic diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58138458A (ja) * 1982-02-10 1983-08-17 信越化学工業株式会社 腸溶性カプセルの製造方法
JPH0725663B2 (ja) * 1985-03-11 1995-03-22 大正製薬株式会社 腸溶性軟カプセルの製造方法
SE9002339L (sv) * 1990-07-04 1992-01-05 Kabi Pharmacia Ab Terapeutisk komposition och foerfarande foer dess framstaellning
JPH0748983B2 (ja) * 1990-12-21 1995-05-31 江崎グリコ株式会社 食用カプセルの製造法
CN1141974C (zh) * 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1208343A (zh) * 1996-01-18 1999-02-17 派利欧产品有限公司 胃肠内释药体系
WO1999018938A1 (en) * 1997-10-09 1999-04-22 Perio Products Ltd. Delayed total release gastrointestinal drug delivery system
WO2000028974A1 (en) * 1998-11-12 2000-05-25 Dexxon Ltd. Local delivery of drugs to the colon for local treatment of colonic diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] ASHFORD MARIANNE ET AL.: "Studies on pectin formulations for colinic", XP002960302, Database accession no. 121:117505 *
J. CONTROLLED RELEASE, vol. 30, no. 3, 1994, pages 225 - 232 *
PORNSAK SRIAMORNSAK, EUR. J. PHARM. SCI., vol. 8, no. 3, 1999, pages 221 - 227, XP002962494 *
See also references of EP1297828A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10844322B2 (en) 2012-08-07 2020-11-24 Ecolab Usa Inc. High flashpoint alcohol-based cleaning, sanitizing and disinfecting composition and method of use on food contact surfaces

Also Published As

Publication number Publication date
BR0111757A (pt) 2004-07-06
EP1297828B1 (en) 2008-12-03
US20040022845A1 (en) 2004-02-05
EP1297828A4 (en) 2007-05-02
DE60136813D1 (de) 2009-01-15
CN1326733A (zh) 2001-12-19
CA2411045A1 (en) 2002-12-06
EP1297828A1 (en) 2003-04-02
AU2001272314A1 (en) 2002-05-27
KR20030023869A (ko) 2003-03-20
JP2004513182A (ja) 2004-04-30
CN1285333C (zh) 2006-11-22

Similar Documents

Publication Publication Date Title
RU2201217C2 (ru) Таблетка с энтеросолюбильным покрытием и способ приготовления
JP5808670B2 (ja) 弱塩基性薬物を含む組成物及び徐放性剤形
EP0523847B1 (en) Taste mask coating for preparation of chewable pharmaceutical tablets
US6893662B2 (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
JP3930562B2 (ja) 結腸送達のための多重腸溶性ポリマーコーティングを有するビサコジル投与形態
JP3350059B2 (ja) 急速に放出し且つ味を隠蔽する医薬剤形
WO2002039982A1 (fr) Composition pharmaceutique a administration orale liberee au niveau colique et son procede de preparation
JP3725542B2 (ja) ピコサルフェート剤形
EP2263656A1 (en) Delayed release pharmaceutical formulations
JP4439499B2 (ja) アムロジピン含有粒子およびそれからなる口腔内崩壊錠
EP1453487A1 (en) Pharmaceutical dosage form with multiple coatings
JP2001527526A (ja) 消化管内での作用物質調整放出用トローチ
CA2121038C (en) Oral preparation for release in lower digestive tracts
JP2004507487A (ja) 腸疾患治療薬
EP3893851A1 (en) Solid oral pharmaceutical compositions for administration of mesalazine or derivatives thereof
JP2000128779A (ja) 薬物放出制御型製剤
JP4705747B2 (ja) 薬剤組成物
JP3122478B2 (ja) 下部消化管放出型経口製剤
JP2006507298A (ja) 経口持続放出型錠剤、ならびにその製造法および使用法
JP2001501642A (ja) 弱酸性薬剤の結腸送達
JPH0774151B2 (ja) 薬物の好ましくない官能的性質を隠蔽した散剤の製造方法
JPH03148215A (ja) 積層製剤
CA2444814C (en) Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
JP5241681B2 (ja) アムロジピン含有粒子およびそれからなる口腔内崩壊錠
Naiserová et al. perorálních tablet

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2002 542357

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2411045

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020027016732

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/1516/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2001951330

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027016732

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001951330

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10297529

Country of ref document: US